Sports Medicine

, Volume 12, Issue 4, pp 250–265 | Cite as

Enhancement of Athletic Performance with Drugs

An Overview
  • Jon C. Wagner
Review Article

Summary

Drug use among athletes has become a recognised problem in sports. Athletes may use drugs for therapeutic indications, for recreational or social reasons, as ergogenic aids or to mask the presence of other drugs during drug testing.

Stimulants were some of the first drugs used and studied as ergogenic aids. Amphetamines may increase time to exhaustion by masking the physiological response to fatigue. Caffeine may improve utilisation of fatty acids as a fuel source thereby sparing muscle glycogen. Cocaine and other sympathomimetic drugs have little or no effect on athletic performance.

Anabolic steroids appear to have the potential to increase lean muscle mass and strength under certain conditions. Human growth hormone may also be used for an anabolic effect, but data on this effect are lacking. Erythropoietin may represent a pharmacological alternative to blood doping by increasing red blood cell mass. The use of narcotic analgesics is not necessarily ergogenic but can be harmful if used to allow participation of an athlete with a severe injury.

According to the American College of Sports Medicine alcohol does not possess an ergogenic effect. However, it may be used to reduce anxiety or tremor prior to competition. Marijuana does not increase strength. Tobacco products may produce psychomotor effects or control appetite which may be beneficial to some athletes.

Other drugs used by athletes include β-blocking agents, diuretics, and a variety of nutritional supplements. In addition, diuretics and probenecid may be taken to mask drug contents in the urine.

Whether the ergogenic effects are real or perceived, the potential for adverse effects exists for all of these drugs. Potential health complications represent a serious risk to an otherwise healthy population. Further research on the long term health risks in athletes taking ergogenic drugs is needed.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alen M, Rahkila P, Marniemi J. Serum lipids in power athletes self-administering testosterone and anabolic steroids. International Journal of Sports Medicine 6: 139–144, 1985PubMedCrossRefGoogle Scholar
  2. Alen M, Rahkila P. Reduced high-density lipoprotein-cholesterol in power athletes: use of male sex hormone derivates, anath-erogenic factor. International Journal of Sports Medicine 5: 341–342, 1984PubMedCrossRefGoogle Scholar
  3. American College of Sports Medicine. The use of alcohol in sports. Medicine and Science in Sports and Exercise 14: 481–482, 1982Google Scholar
  4. Anderson WA, McKeag DB. The substance use and abuse habits of college students-athletes: College of Human Medicine, Michigan State University, East Lansing, Michigan. Presented to the National Collegiate Athletic Association, January, 1985Google Scholar
  5. Anderson WA, McKeag DB. Replication of the national study of the substance use and abuse habits of college student-athletes: College of Human Medicine, Michigan State University, East Lansing, Michigan. Presented to the National Collegiate Athletic Association, October, 1989Google Scholar
  6. Annitto WJ, Layman WA. Anabolic steroids and acute schizophrenic episode. Journal of Clinical Psychiatry 41: 143–144, 1980PubMedGoogle Scholar
  7. Ariel G, Saville W. Anabolic steroids: the physiological effects of placebos. Medicine and Science in Sports 4: 124–126, 1972Google Scholar
  8. Bahrke MS, Yesalis CE, Wright JE. Psychological and behavioural effects of endogenous testosterone levels and anabolic-androgenic steroids among males. Sports Medicine 10: 303–337, 1990PubMedCrossRefGoogle Scholar
  9. Battig KV. Differential effect of nicotine and tobacco smoking alkaloids on swimming endurance in the rat. Psychopharmacologia 18: 300–304, 1970PubMedCrossRefGoogle Scholar
  10. Bhagat B, Wheeler W. Effect of nicotine on the swimming endurance of rats. Neuropharmacology 12: 1161–1166, 1973PubMedCrossRefGoogle Scholar
  11. Bond V, Franks BD, Hawley ET. Effects of small and moderate doses of alcohol on submaximal cardio-respiratory function, perceived exertion and endurance performance in abstainers and moderate drinkers. Journal of Sports Medicine 23: 221–228, 1983Google Scholar
  12. Brower KJ, Blow FC, Beresford TP, Fuelling C. Anabolic-androgenic steroid dependence. Journal of Clinical Psychiatry 50: 31–33, 1989PubMedGoogle Scholar
  13. Buckley WE, Yesalis CE, Friedl KE, Anderson WA, Streit AL, et al. Estimated prevalence of anabolic steroid use among high school seniors. Journal of the American Medical Association 260: 3441–3445, 1988PubMedCrossRefGoogle Scholar
  14. Caldwell JE, Ahonen E, Nousiainen U. Differential effects of sauna-, diuretic-, and exercise-induced hypohydration. Journal of Applied Physiology 57: 1018–1023, 1984PubMedGoogle Scholar
  15. Cantwell JD, Rose FD. Cocaine and cardiovascular events. Physician and Sportsmedicine 11: 77–82, 1986Google Scholar
  16. Chandler JV, Blair SN. The effect of amphetamines on selected physiological components related to athletic success. Medicine and Science in Sports and Exercise 12: 65–69, 1980PubMedGoogle Scholar
  17. Clark DC. Alcohol abuse in medical school. Correspondence. Journal of the American Medical Association 258: 1173, 1987CrossRefGoogle Scholar
  18. Clark N. Social drinking and athletes. Physician and Sportsmedicine 17: 95–100, 1989Google Scholar
  19. Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. Journal of Clinical Endocrinology and Metabolism 64: 960–963, 1987PubMedCrossRefGoogle Scholar
  20. Connolly GN, Orleans CT, Kogan M. Use of smokeless tobacco in major-league baseball. New England Journal of Medicine 318: 1281–1284, 1988PubMedCrossRefGoogle Scholar
  21. Costill DL, Dalsky GP, Fink WJ. Effects of caffeine ingestion on metabolism and exercise performance. Medicine and Science in Sports 10: 155–158, 1978PubMedGoogle Scholar
  22. Cowart VS. Classifying steroids as controlled substances suggested to decrease athletes’ supply, but enforcement could be a major problem. Journal of the American Medical Association 257: 3029, 1987aPubMedCrossRefGoogle Scholar
  23. Cowart VS. Human growth hormone: the latest ergogenic aid? Physician and Sportsmedicine 16: 175–185, 1988Google Scholar
  24. Cowart VS. Would controlled substance status affect steroid trafficking? Physician and Sportsmedicine 15: 151–154, 1987bGoogle Scholar
  25. Creagh TM, Rubin A, Evan DJ. Hepatic tumours induced by anabolic steroids in an athlete. Journal of Clinical Pathology 41: 441–443, 1988PubMedCrossRefGoogle Scholar
  26. Cregler LI, Mark H. Medical complications of cocaine abuse. New England Journal of Medicine 315: 1495–1500, 1986PubMedCrossRefGoogle Scholar
  27. Crist DM, Stackpole PJ, Peake GT. Effects of androgenic-anabolic steroids on neuromuscular power and body composition. Journal of Applied Physiology 54: 336–370, 1983CrossRefGoogle Scholar
  28. Delbeke FT, Debackere M. Caffeine: use and abuse in sports. International Journal of Sports Medicine 5: 179–182, 1984PubMedCrossRefGoogle Scholar
  29. Duda M. NCAA: Only 4% of athletes used steroids. Physician and Sportsmedicine 13: 30, 1985Google Scholar
  30. Duda M. Cocaine deaths may increase drug tests. Physician and Sportsmedicine 14: 37, 1986Google Scholar
  31. Edwards SW, Glover ED, Schroeder KL. The effects of smokeless tobacco on heart rate and neuromuscular reactivity in athletes and nonathletes. Physician and Sportsmedicine 15: 141–147, 1987Google Scholar
  32. Ekblom B. Blood doping, oxygen breathing and altitude training. In Strauss RH (Ed.) Drugs and performance in sports, W.B. Saunders, Philadelphia, 1987Google Scholar
  33. Ekblom B. Effects of iron deficiency, variation in hemoglobin concentration and erythropoeitin injections on physical performance and relevant physiological parameters. 1st International Olympic Committee World Congress on Sport Sciences, Colorado Springs, Oct 28–Nov 3, pp. 9–11, 1989Google Scholar
  34. Emster VL, Grady DG, Greene JC, Walsh M, Robertson F, et al. Smokeless tobacco use and health effects among baseball players. Journal of the American Medical Association 264: 218–224, 1990CrossRefGoogle Scholar
  35. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoeitin: results of a combined Phase I and II clinical trial. New England Journal of Medicine 316: 73–78, 1987PubMedCrossRefGoogle Scholar
  36. Fahey TD, Brown CH. The effects of anabolic steroid on the strength, body composition, and endurance of college males when accompanied by a weight training program. Medicine and Science in Sports 5: 272–276, 1973PubMedGoogle Scholar
  37. Farrell GC, Joshua DE, Uren RF, Baird PJ, Perkins KW, et al. Androgen-induced hepatoma. Lancet 1: 430–432, 1975PubMedCrossRefGoogle Scholar
  38. Frankle MA, Eichberg R, Zachariah SB. Anabolic androgenic Steroids and a stroke in an athlete: case report. Archives of Physical Medicine and Rehabilitation 69: 632–633, 1988PubMedGoogle Scholar
  39. Franks HM, Hagedorn H, Hensley VA, Hensley WS, Starmer GA. The effect of caffeine on human performance alone and in combination with ethanol. Psychopharmacologia 45: 177–181, 1975PubMedCrossRefGoogle Scholar
  40. Freed DLJ, Banks AJ, Longson D, Burley DM. Anabolic steroids in athletics: crossover double-blind trial on weightlifters. British Medical Journal 2: 471–473, 1975PubMedCrossRefGoogle Scholar
  41. Friedl KE, Yesalis CE. Self-treatment of gynecomastia in bodybuilders who use anabolic steroids. Physician and Sportsmedicine 17: 67–79, 1989Google Scholar
  42. Freinhar J, Alvarez W. Androgen-induced hypomania. Correspondence. Journal of Clinical Psychiatry 46: 354–345, 1985PubMedGoogle Scholar
  43. Frohman LA. Diseases of the anterior pituitary. In Felig P, et al. (Eds) Endocrinology and metabolism, 2nd ed., McGraw-Hill, New York, 1987Google Scholar
  44. Giammarco RA. The athlete, cocaine and lactic acidosis: a hypothesis. American Journal of Medical Sciences 294: 412–414, 1987CrossRefGoogle Scholar
  45. Goldman B. Liver carcinoma in an athlete taking anabolic steroids. Journal of the American Osteopathic Association 85: 56, 1985PubMedGoogle Scholar
  46. Hagerman FC, Jones-Witters P, Ranson R. The effects of anabolic steroid ingestion on serum enzyme and urine 17-ketosteroid levels. Metabolism 32: 413–420, 1983CrossRefGoogle Scholar
  47. Haupt HA, Rovere GD. Anabolic steroids: a review of the literature. American Journal of Sports Medicine 12: 469–484, 1984PubMedCrossRefGoogle Scholar
  48. Haupt HA. Drugs in athletics. Clinics in Sports Medicine 8: 561–580, 1989PubMedGoogle Scholar
  49. Hervey GR, Hutchinson I, Knibbs AV, Burkinshow L, Jones PRM, et al. ‘Anabolic’ effects of methandione in men undergoing athletic training. Lancet 2: 699–702, 1976PubMedCrossRefGoogle Scholar
  50. Hervey GR, Knibbs AV, Burkinshaw L, Morgan DB, Jones PRM, et al. Effects of methandierone on the performance and body composition of men undergoing athletic training. Clinical Science 60: 457–461, 1981PubMedGoogle Scholar
  51. Hickson RC, Ball KL, Falduto MT. Adverse effects of anabolic steroids. Medical Toxicology and Adverse Drug Experience 4: 254–271, 1989PubMedGoogle Scholar
  52. Hurley BF, Seals DR, Hagberg JM, Goldberg AC, Ostrove SM, et al. High density-lipoprotein cholesterol in bodybuilders v powerlifters: negative effects of androgen use. Journal of the American Medical Association 252: 507–513, 1984PubMedCrossRefGoogle Scholar
  53. Ivy JL, Costill DL, Fink WJ, Lower RW. Influence of caffeine and carbohydrate feedings on endurance performance. Medicine and Science in Sports 11: 6–11, 1979PubMedGoogle Scholar
  54. Jacobson BH. Effect of amino acids on growth hormone release. Physician and Sportsmedicine 18: 63–69, 1990Google Scholar
  55. Jaffe JH. Drug addiction and drug abuse. In Gillman AG, et al. (Eds) Goodman and Gillman’s the pharmacological basis of therapeutics, 7th ed., Macmillan, New York, 1985Google Scholar
  56. Johnson LC, Roundy ES, Allsen PE, et al. Effect of anabolic steroid treatment on endurance. Medicine and Science in Sports 7: 287–289, 1975PubMedGoogle Scholar
  57. Johnson MD, Jay MS, Shoup B, Rickert VI. Anabolic steroid use by male adolescents. Pediatrics 83: 921–924, 1989PubMedGoogle Scholar
  58. Jones RB. Use of smokeless tobacco in the 1986 World Series. Correspondence. New England Journal of Medicine 316: 852, 1987Google Scholar
  59. Kaiser P. Physical performance and muscle metabolism during β-adrenergic blockade in man. Acta Physiologica Scandinavica 536 (Suppl.): 1–53, 1984Google Scholar
  60. Karpovich PV. Effect of amphetamine sulfate on athletic performance. Journal of the American Medical Association 170: 558–561, 1959PubMedCrossRefGoogle Scholar
  61. Kashkin KB, Kleber HD. Hooked on hormones? Anabolic steroid addiction hypothesis. Journal of the American Medical Association 262: 3166–3170, 1989PubMedCrossRefGoogle Scholar
  62. Kibble MW, Ross MB. Adverse effects of anabolic steroids in athletes. Clinical Pharmacy 6: 686–692, 1987PubMedGoogle Scholar
  63. Klausen K, Anderson S, Nandrup S. Acute effects of cigarette smoking and inhalation of carbon monoxide during maximal exercise. European Journal of Applied Physiology 51: 371–379, 1983CrossRefGoogle Scholar
  64. Kleiner SM, Calabrese LH, Fielder KM, Naito HK, Skibinski CI. Dietary influences on cardiovascular disease risk in anabolic steroid using and non-using bodybuilders. Journal of the American College of Nutrition 8: 109–119, 1989PubMedGoogle Scholar
  65. Koller WC, Biary N. Effect of alcohol on tremors: comparison with propranolol. Neurology 34: 221–222, 1984PubMedCrossRefGoogle Scholar
  66. Kruse P, Ladefoged J, Nielson U, Pauler P, Sorensen JP. β-Blockade used in precision sports: effect on pistol shooting performance. Journal of Applied Physiology 61: 417–420, 1986PubMedGoogle Scholar
  67. Lamb DR. Anabolic steroids in athletics: how well do they work and how dangerous are they? American Journal of Sports Medicine 12: 31–38, 1984PubMedCrossRefGoogle Scholar
  68. Langston JW, Langston EB. Neurological consequences of drug abuse. In Asbury AK, et al. (Eds) Diseases of the nervous system: clinical neurobiology, W.B. Saunders, Philadelphia, 1986Google Scholar
  69. Laseter JT, Russell JA. Anabolic steroid-induced tendon pathology: a review of the literature. Medicine and Science in Sports and Exercise 22: 1–3, 1991Google Scholar
  70. Laties VG, Weiss B. The amphetamine margin in sports. Federation Proceedings 40: 2689–2692, 1981PubMedGoogle Scholar
  71. Lipids Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial: results: I. Reduction in incidence of coronary heart disease. Journal of the American Medical Association 251: 351–364, 1984CrossRefGoogle Scholar
  72. Lombardo JA. Drugs in sports. In Krakauer LJ (Ed.) The 1986 yearbook in sports medicine, Yearbook Publishers, Chicago, 1986Google Scholar
  73. Lombardo JA. Stimulants. In Strauss RH (Ed.) Drugs and performance in sports, W.B. Saunders, Philadelphia, 1987Google Scholar
  74. Lowenstein DH, Massa SM, Rowbotham MC, Collins SD, McKinney HE, et al. Active neurological and psychiatric complications associated with cocaine abuse. American Journal of Medicine 83: 841–846, 1987PubMedCrossRefGoogle Scholar
  75. Macintyre JG. Growth hormone and athletes. Sports Medicine 294: 412–414, 1987Google Scholar
  76. Maskud MC, Baron A. Physiological responses to exercise in chronic cigarette and marijuana users. European Journal of Applied Physiology 43: 127–134, 1980CrossRefGoogle Scholar
  77. Mays ET, Christopherson LO. Hepatic tumors induced by sex steroids. Seminars in Liver Disease 4: 147–157, 1984PubMedCrossRefGoogle Scholar
  78. McKillop G, Ballantyne D. Lipoprotein analysis in bodybuilders. International Journal of Cardiology 17: 281–286, 1987PubMedCrossRefGoogle Scholar
  79. McNaughton L, Preece D. Alcohol and its effect on sprint and middle distance running. British Journal of Sports Medicine 14: 481–482, 1982Google Scholar
  80. McNutt RA, Ferenchick GS, Kirlin PC, Hamlin NJ. Acute myocardial infarction in a 22-year-old world class weight lifter using anabolic steroids. American Journal of Cardiology 62: 164, 1988PubMedCrossRefGoogle Scholar
  81. Morrison C. Effect of nicotine on operant behavior of rats. International Journal of Neuropharmacology 6: 229–240, 1967PubMedCrossRefGoogle Scholar
  82. Murad F, Haynes RC. Androgens. In Gillman AG, et al. (Eds) Goodman and Gillman’s the pharmacological basis of therapeutics, 7th ed., Macmillan, New York, 1985Google Scholar
  83. Murphy P. Steroids: not just for athletes any more. Physician and Sportsmedicine 14: 48, 1986Google Scholar
  84. Murray TH. The coercive power of drugs in sports. Hastings Center Report 13: 24–30, 1983PubMedGoogle Scholar
  85. National Collegiate Athletic Association. The 1989/90 NCAA drugtesting/education programs, Mission, KS: National Collegiate Athletic Association, 1989Google Scholar
  86. Nelson D. Effects of ethyl alcohol on the performance of selected gross motor tests. Research Quarterly 30: 312–320, 1959Google Scholar
  87. Newman NM, DiLoreto DA, Ho JT, Klein JC, Birnbaum NS. Bilateral optic neuropathy and osteolytic sinusitis: complications of cocaine abuse. Journal of the American Medical Association 259: 72–74, 1988PubMedCrossRefGoogle Scholar
  88. Overly WL, Dankoff JA, Wang BK, Singh VD. Androgens and hepatocellular carcinoma in an athlete. Annals of Internal Medicine 100: 158–159, 1984PubMedGoogle Scholar
  89. O’Shea JP. Anabolic steroid: effects on competitive swimmers. Nutrition Reports International 1: 337–342, 1970Google Scholar
  90. O’Shea JP, Winkler W. Biochemical and physical effects on an anabolic steroid in competitive swimmers and weightlifters. Nutrition Reports International 2: 351–362, 1970Google Scholar
  91. Pentel P. Toxicity of over-the-counter stimulants. Journal of American Medical Association 252: 1898–1903, 1984CrossRefGoogle Scholar
  92. Percy EC. Ergogenic aids in athletes. Medicine and Science in Sports and Exercise 10: 298–303, 1982Google Scholar
  93. Pope H, Katz D. Bodybuilder’s psychosis. Correspondence. Lancet 1: 863, 1987PubMedCrossRefGoogle Scholar
  94. Pope HG, Katz DL. Affective and psychotic symptoms associated with anabolic steroid use. American Journal of Psychiatry 145: 487–490, 1988PubMedGoogle Scholar
  95. Pope HG, Katz DL. Homicide and near-homicide by anabolic steroid users. Journal of Clinical Psychiatry 51: 28–31, 1990PubMedGoogle Scholar
  96. Puffer J. The use of drugs in swimming. Clinics in Sports Medicine 5: 77–89, 1986PubMedGoogle Scholar
  97. Rall TW. Central nervous stimulants — the methylxanthines. In Gilman AG, et al. (Eds) Goodman and Gillman’s the pharmacological basis of therapeutics, 7th ed., Macmillan, New York, 1985Google Scholar
  98. Ritchie JM, Green NM. Local anesthetics. In Gillman AG, et al. (Eds) Goodman and Gillman’s the pharmacological basis of therapeutics, 7th ed., Macmillan, New York, 1985Google Scholar
  99. Rogozkin V. Metabolic effects of anabolic steroid on skeletal muscle. Medicine and Science in Sports 11: 160–163, 1979PubMedGoogle Scholar
  100. Ryan AJ. Anabolic steroids are fool’s gold. Federation Proceedings 40: 2682–2688, 1981PubMedGoogle Scholar
  101. Schuster C, Fischman M. Amphetamine toxicity. Behavioural and neuropathological indexes. Federation Proceedings 34: 1845–1851, 1975PubMedGoogle Scholar
  102. Shephard RJ, Killinger D, Fried T. Responses to sustained use of anabolic steroids. British Journal of Sports Medicine 11: 170–173, 1977PubMedCrossRefGoogle Scholar
  103. Sidney KH, Lefcoe WM. The effects of ephedrine on the physiological and psychological responses to submaximal and maximal exercises in man. Medicine and Science in Sports 9: 95–99, 1977PubMedGoogle Scholar
  104. Sklarek HM, Mantovani RP, Evans E, Heisler D, Niederman MS, et al. AIDS in a bodybuilder using anabolic steroids. New England Journal of Medicine 311: 1701, 1984PubMedGoogle Scholar
  105. Smith GM, Beecher HK. Amphetamine sulfate and athletic performance. Journal of the American Medical Association 170: 542–557, 1959PubMedCrossRefGoogle Scholar
  106. Steadward RD, Singh M. The effects of smoking marihuana on physical performance. Medicine and Science in Sports 7: 309–311, 1975PubMedGoogle Scholar
  107. Strauss RH. Anabolic steroids. In Strauss RH (Ed.) Drugs and performance in sports, W.B. Saunders, Philadelphia, 1987Google Scholar
  108. Strauss RH, Liggett MT, Lanese RR. Anabolic steroids use and perceived effects in ten weight trained women athletes. Journal of the American Medical Association 253: 2871–2874, 1985PubMedCrossRefGoogle Scholar
  109. Straus RH, Wright JE, Finerman GAM. Anabolic steroid use and health status among forty-two weight-trained male athletes. Abstract. Medicine and Science in Sports and Exercise 14: 119, 1982Google Scholar
  110. Strauss RH, Wright JE, Finerman GAM, Catlin DH. Side effects of anabolic steroids in weight-trained men. Physician and Sportsmedicine 11: 87–101, 1983Google Scholar
  111. Stromme SB, Meen HD, Aakvaag A. Effects of an androgenic-anabolic steroid on strength development and plasma testosterone levels in normal males. Medicine and Science in Sports and Exercise 6: 203–208, 1974Google Scholar
  112. Sussman S, Barovich M. Smokeless tobacco: less seen at 1988 World Series. American Journal of Public Health 79: 521–522, 1989PubMedCrossRefGoogle Scholar
  113. Taylor WN. Synthetic anabolic-androgenic steroids: a plea for controlled substance status. Physician and Sportsmedicine 15: 140–150, 1987Google Scholar
  114. Tennant F, Black DL, Voy RO. Anabolic steroid dependence with opioid-type features. Correspondence. New England Journal of Medicine 319: 578, 1988PubMedCrossRefGoogle Scholar
  115. Thomason H. Drugs and the athlete. In Davies B, et al. (Eds) Science and sporting performance: management or manipulation? Oxford University Press, Oxford, 1982Google Scholar
  116. Ulrich AK, Maniera H, Nieschlag E. Anabolic steroids and semen parameters in body builders. Fertility and Sterility 52: 1041–1047, 1989Google Scholar
  117. United States Olympic Committee. Guide to banned medications. Sportsmediscope 7: 1–5, 1988Google Scholar
  118. United States Olympic Committee. USOC drug control program protocol, 1990, U.S. Olympic House, Colorado Springs, 1990Google Scholar
  119. van der Merwe PJ, Müller FR, Müller FO. Caffeine in sport: urinary excretion of caffeine in healthy volunteers after intake of common caffeine-containing beverages. South African Medical Journal 74: 163–164, 1988PubMedGoogle Scholar
  120. Wadler GI, Hainline B. Drugs and the athlete, F.A. Davis, Philadelphia, 1989Google Scholar
  121. Wagner JC. Abuse of drugs used to enhance athletic performance. American Journal of Hospital Pharmacy 46: 2059–2067, 1989aPubMedGoogle Scholar
  122. Wagner JC. Use of chromium and cobalamide by athletes. Clinical Pharmacy 8: 832–834, 1989bGoogle Scholar
  123. Waitley DE, May JR, Martens R. Sports psychology and the elite athlete. Clinics in Sports Medicine 2: 87–99, 1983PubMedGoogle Scholar
  124. Weight LM, Myburgh KH, Noakes TD. Vitamin and mineral supplementation: effect on the running performance of trained athletes. American Journal of Clinical Nutrition 47: 192–195, 1988PubMedGoogle Scholar
  125. Weiner N. Norepinephrine, epinephrine and the sympathomimetic amines. In Gilman AG, et al. (Eds) Goodman and Gillman’s the pharmacological basis of therapeutics, 7th ed., Macmillan, New York, 1985Google Scholar
  126. Weiss RJ. Recurrent myocardial infarction caused by cocaine abuse. American Heart Journal 111: 793, 1986PubMedCrossRefGoogle Scholar
  127. Wilson I, Prange A, Lara P. Methytestosterone with imipramine in men — conversion of depression to paranoid reaction. American Journal of Psychiatry 131: 21–24, 1974PubMedGoogle Scholar
  128. Wilson JD, Griffin JE. The use and misuse of androgens. Metabolism 29: 1278–1295, 1980PubMedCrossRefGoogle Scholar
  129. Windsor RE, Dumitru D. Anabolic steroid use by athletes. Postgraduate Medicine 84: 37–49, 1984Google Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Jon C. Wagner
    • 1
  1. 1.College of PharmacyUniversity of Nebraska Medical CenterOmahaUSA

Personalised recommendations